Steve Seedhouse

Stock Analyst at Cantor Fitzgerald

(4.23)

# 505

Out of 5,111 analysts

11

Total ratings

80%

Success rate

13.8%

Average return

Main Sectors:

Top Industries:

Biotechnology Drug Manufacturers - Specialty & Generic

Stocks Rated by Steve Seedhouse

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	WVE Wave Life Sciences	Maintains: Overweight	$12 → $34	$16.41	+107.19%	1	Dec 9, 2025
	BLTE Belite Bio	Assumes: Overweight	$154	$149.13	+3.27%	1	Nov 24, 2025
	KRRO Korro Bio	Downgrades: Neutral	n/a	$8.22	-	1	Nov 13, 2025
	XNCR Xencor	Maintains: Overweight	$40 → $42	$16.55	+153.78%	2	Nov 6, 2025
	INVA Innoviva	Maintains: Overweight	$29 → $31	$19.92	+55.62%	2	Nov 6, 2025
	CAMP Camp4 Therapeutics	Initiates: Overweight	$7	$7.01	-0.14%	1	Oct 2, 2025
	APLS Apellis Pharmaceuticals	Maintains: Overweight	$39 → $40	$25.31	+58.04%	1	Aug 1, 2025
	TVRD Tvardi Therapeutics	Initiates: Overweight	$52	$4.20	+1,138.10%	1	Jul 11, 2025
	HROW Harrow	Initiates: Overweight	$76	$44.77	+69.76%	1	Jul 11, 2025

Wave Life Sciences

Dec 9, 2025

Maintains: Overweight

Price Target: $12 → $34

Current: $16.41

Upside: +107.19%

Belite Bio

Nov 24, 2025

Assumes: Overweight

Price Target: $154

Current: $149.13

Upside: +3.27%

Korro Bio

Nov 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $8.22

Upside: -

Xencor

Nov 6, 2025

Maintains: Overweight

Price Target: $40 → $42

Current: $16.55

Upside: +153.78%

Innoviva

Nov 6, 2025

Maintains: Overweight

Price Target: $29 → $31

Current: $19.92

Upside: +55.62%

Camp4 Therapeutics

Oct 2, 2025

Initiates: Overweight

Price Target: $7

Current: $7.01

Upside: -0.14%

Apellis Pharmaceuticals

Aug 1, 2025

Maintains: Overweight

Price Target: $39 → $40

Current: $25.31

Upside: +58.04%

Tvardi Therapeutics

Jul 11, 2025

Initiates: Overweight

Price Target: $52

Current: $4.20

Upside: +1,138.10%

Harrow

Jul 11, 2025

Initiates: Overweight

Price Target: $76

Current: $44.77

Upside: +69.76%